Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University
• Treatments: Everolimus; Lenvatinib; Trametinib

Criteria

Inclusion Criteria:

• Recurrent/Refractory advanced solid tumors

• Age between 18 and 85 years

• Expected life expectancy is greater than three months

Exclusion Criteria:

• Benign tumor

• Life expectancy is less than three months

• Serious medical commodities

• others